Biotron Advances SedRx Regulatory Pathway and Broadens Antiviral Scope with $878K Raise

Sedarex Integration Completes, SedRx Regulatory Push Gains Momentum

Biotron Limited (ASX:BIT) has wrapped up the corporate and operational integration of Sedarex Limited, acquired in December 2025, marking a key milestone in its diversification strategy. Sedarex’s flagship product, SedRx, is a next-generation general anaesthetic leveraging alfaxalone, an active ingredient with a proven track record in Europe. Importantly, SedRx aims to overcome safety concerns linked to its predecessor Althesin, maintaining cognitive function post-procedure; a significant advantage in the anaesthetics market.

The company is actively preparing a submission to the European Medicines Agency (EMA) for scientific advice on the regulatory pathway for SedRx, targeting an abridged approval process under the EMA framework, akin to the FDA’s 505(b)(2) pathway. Biotron expects formal guidance before the 31 July 2026 deadline, a condition tied to the acquisition terms. This regulatory push is supported by positive Phase 1 and pilot Phase 2a data demonstrating superior safety and cognitive outcomes compared to leading anaesthetics.

BIT-HBV001 Expands Antiviral Reach to Hepatitis Delta Virus

On the antiviral front, Biotron’s lead compound BIT-HBV001, initially developed for Hepatitis B virus (HBV), has shown promising activity against Hepatitis Delta Virus (HDV), a satellite virus that co-infects HBV-positive patients and drives the most severe forms of viral hepatitis. In cell studies conducted at the SCRIPPS Institute in San Diego, BIT-HBV001 inhibited HDV antigen production by approximately 85% relative to untreated controls, suggesting potential to address a significant unmet medical need in HBV/HDV co-infection.

This development broadens the therapeutic scope of BIT-HBV001 beyond HBV, where it has already demonstrated strong antiviral effects in multiple cell-based assays and animal models. The extension into HDV could position Biotron’s candidate as a component of future functional cure therapies for severe hepatitis infections, a space with limited effective treatments currently.

Capital Raise Completes Funding Round, Board Changes Announced

Financially, Biotron closed the shortfall tranche of its non-renounceable rights issue in late January 2026, raising an additional $878,733 before costs and bringing the total raised under this issue to $1.52 million. This fresh capital injection bolsters the company’s cash position, which stood at $1.78 million at quarter end, supporting ongoing R&D and regulatory activities. Quarterly expenditure on research and development was $128,000, with related staff costs of $142,000, reflecting a lean operational approach.

Governance updates include the appointment of Dr Graeme Wald as a Non-Executive Director in March 2026, following the retirement of Robert B. Thomas in February. This board refreshment aligns with Biotron’s evolving strategic focus as it advances its diversified biotech portfolio.

Investors may recall that Biotron’s recent progress with BIT-HBV001 and Sedarex integration follows a series of capital raises and operational milestones, including the earlier $2.5 million capital raise that underpinned the acquisition and initial development phases fully subscribed rights issue. The expanded antiviral profile of BIT-HBV001 was first highlighted in March 2026, underscoring the compound’s growing clinical relevance BIT-HBV001 Targets Hepatitis Delta.